A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like ...

Federal law allows compounding pharmacies to make copies of name brand drugs while there’s a supply shortage. But there's a ...

New research found hospital visits from Ozempic and Wegovy are rare, but can be serious. Experts explain the finding and ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

As Senators Chris Van Hollen, Cory Booker, and Congresswoman Alexandria Ocasio-Cortez are showing, there is huge political ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Novo Nordisk (NYSE: NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...

Americans shelled out an estimated $71 billion for weight-loss drugs in 2023 - that is as much as the U.S. government disbursed in foreign aid the same year, according to ForeignAssistance.gov.

Novo Nordisk has awarded a 50 million kroner ($7.6M) grant to the University of Copenhagen to develop less processed ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...